Skip to main content
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · XENE ISIN · CA98420N1050 LEI · 549300XV44Q9Z1MIPQ03 US Manufacturing
Open in API
Filings indexed 746 across all filing types
Latest filing 2018-07-03 Capital/Financing Update
Country CA Canada
Listing US XENE

About Xenon Pharmaceuticals Inc.

https://www.xenon-pharma.com/

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to the discovery, clinical development, and commercialization of therapeutics for neurological and psychiatric disorders. The company leverages its expertise in human genetics and a deep understanding of ion channel biology to develop medicines that modulate ion channels, targeting the central and peripheral nervous systems. Its late-stage pipeline includes azetukalner, an investigational candidate being developed for the treatment of epilepsy and depression.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes an 'at-the-market' equity offering sales agreement and the proceeds from shares sold under this program. This is an update on the company's financing activities, specifically equity fundraising. The document length is 2930 characters, which is relatively short and consistent with an announcement rather than a full financial report. The key event is a capital raising transaction, so the appropriate classification is 'Capital/Financing Update' (CAP).
2018-07-03 English
XENON PHARMACEUTICALS INC.
Major Shareholding Notification
2018-07-03 English
FORM 4
Director's Dealing
2018-06-22 English
FORM 4
Director's Dealing
2018-06-22 English
OWNERSHIP DOCUMENT
Director's Dealing
2018-06-16 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a loan modification agreement with Silicon Valley Bank, detailing changes to the loan terms and financial obligations. There are no financial statements or comprehensive financial data presented, only a description of the financing update. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is sufficient and the content is substantive about financing terms, not merely an announcement of a report or certification. Therefore, the correct classification is CAP with high confidence.
2018-06-13 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.